Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Delanzomib + Tinostamustine |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Delanzomib | CEP-18770|CEP18770|NPH-007098 | Delanzomib (CEP-18770) inhibits proteosome chymotrypsin-like activity, potentially resulting in increased tumor cell death (PMID: 18057228, PMID: 25935605, PMID: 23058787, PMID: 28140719). | ||
Tinostamustine | EDO-S101|EDOS101|EDO S101 | Chemotherapy - Alkylating 18 HDAC Inhibitor 45 | Tinostamustine (EDO-S101) comprises the structure of the DNA alkylating drug bendumustine combined with the pan-HDAC inhibitor vorinostat, which may both induce DNA damage and inhibit DNA repair resulting in increased tumor cell death (PMID: 28753594, PMID: 32099034, PMID: 31372848). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|